Optimal epilepsy management in teenage patients represents a particular challenge. These patients are often likely to respond more positively to a regimen that least disrupts their activities. In addition, as a patient group, they are more sensitive to peer perception. Current perceptions of older antiepilepsy drugs do not take into account frequent undesirable side effects or potential adverse interactions with other drugs. Furthermore, they often do not completely control seizures. Recent data suggest that not only do the newer antiepileptic drugs appear to be as efficacious as the older drugs, they also often have more favorable cognitive, cosmetic, and teratogenic side-effect profiles. In addition, newer antiepileptic drugs are being used more often in monotherapy. Successful management of epilepsy in teenagers requires that physicians not only understand the advantages that the newer antiepileptic drugs appear to provide but also consider the social impact of treatment on their patients. (J Child Neurol 2006; 21: 273—279; DOI 10.2310/7010.2006.00069).
Get full access to this article
View all access options for this article.
References
1.
Nordli DR Jr : Special needs of the adolescent with epilepsy. Epilepsia2001;42(Suppl 8):10—17.
2.
Wheless JW, Kim HL: Adolescent seizures and epilepsy syndromes. Epilepsia2002;43(Suppl 3):S33—S52.
3.
Sheth RD: Adolescent issues in epilepsy. J Child Neurol2002;17(Suppl 2):2523—2527.
4.
Nevins TE: Non-compliance and its management in teenagers. PediatrTransplant2002;6:475—479.
5.
International League Against Epilepsy: Adolescent epilepsy. Epilepsia2003;44(Suppl 6):73—74.
6.
Freitag CM, May TW, Pfäfflin M., et al: Incidence of epilepsies and epileptic syndromes in children and adolescents: A population-based prospective study in Germany. Epilepsia2001;42:979—985.
7.
Kanner AM, Balabanov A.: Depression and epilepsy: How closely related are they?Neurology2002; 58(Suppl 5):S27—S39.
8.
Harden CL: The co-morbidity of depression and epilepsy: Epidemiology, etiology, and treatment . Neurology2002;59(Suppl 4):S48—S55.
9.
Ettinger AB, Weisbrot DM, Nolan EE, et al: Symptoms of depression and anxiety in pediatric epilepsy patients . Epilepsia1998;39:595—599.
10.
Barry JJ: The recognition and management of mood disorders as a comorbidity of epilepsy . Epilepsia2003;44(Suppl 4):30—40.
11.
Plioplys S. : Depression in children and adolescents with epilepsy. Epilepsy Behav2003; 4 (Suppl 3):S39-S45.
12.
Kramer G.: Broadening the perspective: Treating the whole patient. Epilepsia2003;44(Suppl 5):16—22.
13.
Pellock JM: Understanding co-morbidities affecting children with epilepsy. Neurology2004; 62(Suppl 2):S17—S23.
14.
Rutecki PA, Gidal BE: Antiepileptic drug treatment in the developmentally disabled: Treatment considerations with the newer antiepileptic drugs. Epilepsy Behav2002; 3(6 Suppl 1):24—31.
15.
Kyngäs H.: Compliance of adolescents with chronic disease. J Clin Nurs2000;4:549—556.
16.
Buck D., Jacoby A., Baker GA, Chadwick DW: Factors influencing compliance with antiepileptic drug regimes. Seizure1997;6:87—93.
17.
Anderson GD , Kim H., Warner MH: Impact of taking antiepileptic drugs at school in a group of children and adolescents. Epilepsy Behav2000;1:17—21.
18.
Doughty J., Baker GA, Jacoby A., Lavaud V.: Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav2003;4:710—716.
19.
Benavente-Aguilar I., Morales-Blánquez C., Rubio EA, Rey JM: Quality of life of adolescents suffering from epilepsy living in the community. J Paediatr Child Health2004;40:110—113.
20.
Hirsch E., Schmitz B., Carreño M.: Epilepsy, antiepileptic drugs (AEDs) and cognition. Acta Neurol Scand Suppl2003;180:23—32.
21.
Smith Pem, Wallace SJ: Taking over epilepsy from the paediatric neurologist. J Neurol Neurosurg Psychiatry2003;74 (Suppl 1):i37—i41.
22.
Loring DW, Meador KJ: Cognitive and behavioral effects of epilepsy treatment. Epilepsia2001;42(Suppl 8):24—32.
23.
Ortinski P. , Meador KJ: Cognitive side effects of antiepileptic drugs . Epilepsy Behav2004; 5(Suppl 1): S60—S65.
24.
Loring DW, Meador KJ: Cognitive side effects of antiepileptic drugs in children. Neurology2004; 62: 872—877.
25.
Smith DB, Mattson RH, Cramer JA, et al: Results of a nationwide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia1987;28(Suppl 3):S50—S58.
26.
Gordon E., Devinsky O.: Alcohol and marijuana: Effects on epilepsy and use by patients with epilepsy . Epilepsia2001;42:1266—1272.
27.
Biton V., Levisohn P., Hoyler S., et al: Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: Results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol2003;18:133—139.
28.
Kossoff EH, Krauss GL, McGrogan JR, Freeman JM: Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology2003;61:1789—1791.
29.
Mady MA, Kossoff EH, McGregor AL, et al: The ketogenic diet: Adolescents can do it, too. Epilepsia2003;44:847—851.
30.
Sheth RD, Stafstrom CE: Intractable pediatric epilepsy: Vagal nerve stimulation and the ketogenic diet. Neurol Clin2002;20: 1183—1194.
31.
Patsalos PN , Fröscher W., Pisani F., van Rijn CM: The importance of drug interactions in epilepsy therapy. Epilepsia2002;43:365—385.
32.
French JA, Kanner AM, Bautista J., et al: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology2004; 62: 1252—1260.
33.
Pylvänen P. , Knip M., Pakarinen A., et al: Serum insulin and leptin levels in valproate-associated obesity. Epilepsia2002 ;43:514—517.
34.
Biton V., Mirza W., Montouris G., et al: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology2001; 56:172-177.
35.
Jallon P., Picard F.: Bodyweight gain and anticonvulsants: A comparative review. Drug Saf2001; 24: 969—978.
36.
French JA, Kanner AM, Bautista J., et al: Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology2004; 62: 1261—1273.
37.
Richardson SP, Farias ST, Lima AR III, Alsaadi TM: Improvement in seizure control and quality of life in medically refractory epilepsy patients converted from polypharmacy to monotherapy. Epilepsy Beha v2004; 5: 343—347.
38.
Matsuura M. : Patient satisfaction with polypharmacy reduction in chronic epileptics. PsychiatryClin Neurosci2000;54:249—253.
39.
LaRoche SM, Helmers SI: The new antiepileptic drugs: Scientific review. JAMA2004;291:605—614.
40.
Serdaroglu G., Kurul S., Tutuncuoglu S., Dirik E., et al: Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol2003;28:37—41.
41.
Glauser TA, Pellock JM, Bebin EM, et al: Efficacy and safety of levetiracetam in children with partial seizures: An open-label trial. Epilepsia2002 ;43:518—524.
42.
Kwan P., Brodie MJ: Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology2003; 60 (Suppl 4):S2—S12.
43.
Cramer JA, Hammer AE, Kustra RP: Improved mood status with lamotrigine in patients with epilepsy. Epilepsy Behav2004;5: 702—707.
44.
Kaminow L., Schimschock JR, Hammer AE, Vuong A.: Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav2003;4:659—666.
45.
Faught E., Matsuo FU, Schacter S., et al: Long-term tolerability of lamotrigine: Data from a 6-year continuation study. Epilepsy Behav2004;5:31—36.
46.
Aldenkamp AP, DeKrom M., Reijs R.: Newer antiepileptic drugs and cognitive issues. Epilepsia2003;44(Suppl 4):21—29.
Aldenkamp AP, Baker G.: A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav2001;2:85—91.
49.
Biton V., Montouris GD, Ritter F., et al: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology1999;52: 1330—1337.
50.
Morrell MJ, Isojärvi J., Taylor AE, et al: Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res2003 ;54:189—199.
51.
Devinsky O. , Vuong A., Hammer A., Barrett PS: Stable weight during lamotrigine therapy: A review of 32 studies. Neurology2000;54:973—975.
52.
Gidal BE, Sheth RD, Magnus L., Herbeuval AFLevetiracetam does not alter body weight: Analysis of randomized, controlled clinical trials. Epilepsy Res2003;56:121—126.
53.
Bergen DC, Ristanovic RK, Waicosky K., et al: Weight loss in patients taking felbamate. Clin Neuropharmacol1995;18:23—27.
54.
Carmant L., Holmes GL, Sawyer S., et al: Efficacy of felbamate in therapy for partial epilepsy in children . J Pediatr1994;125:481—486.
55.
Biton V.: Effect of antiepileptic drugs on bodyweight: Overview and clinical implications for the treatment of epilepsy. CNSDrugs2003 ;17:781—791.
56.
DeToledo JC , Toledo C., DeCerce J., Ramsay RE: Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit1997;19:394—396.
57.
Chadwick D. for the Vigabatrin European Monotherapy Study Group: Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study. Lancet1999;354:13—19.
58.
Edwards KR, Sackellares JC, Vuong A., et al: Lamotrigine monotherapy improves depressive symptoms in epilepsy: A double-blind comparison with valproate. Epilepsy Beha v2002; 2: 28—36.
59.
Sheth RD, Hobbs GR, Riggs JE, Penney S.: Bone mineral density in geographically diverse adolescent populations. Pediatrics1996;98:948—951.
60.
Sheth RD: Bone health in epilepsy. Epilepsia2002;43:1453—1454.
61.
Verrotti A. , Greco R., Latini G., et al: Increased bone turnover in pre-pubertal, pubertal and postpubertal patients receiving carbamazepine. Epilepsia2002;43:1488—1492.
62.
Farhat G., Yamout B., Mikati MA, et al: Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology2002;58: 1348—1353.
63.
Sheth RD, Wesolowski CA, Jacob JC, et al: Effect of carbamazepine and valproate on bone mineral density . J Pediatr1995;127:256—262.
64.
Pack AM, Olarte LS, Morrell MJ, et al: Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav2003;4:169—174.
65.
Sheth RD: Bone health in epilepsy. Lancet Neurol2004 ; 3: 516.
66.
Tatum WO IV , Liporace J., Benbadis SR, Kaplan PW: Updates on the treatment of epilepsy in women . Arch Intern Med2004; 164:137—145.
67.
Barrett C., Richens A.: Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop . Epilepsy Res2003; 52:147—187.
68.
Kaaja E., Kaaja R., Hiilesmaa V.: Major malformations in offspring of women with epilepsy. Neurology2003; 60: 575—579.
69.
Pennell PB: The importance of monotherapy in pregnancy. Neurology2003; 60 (Suppl 4): S31—S38.
70.
Dansky LV, Rosenblatt DS, Andermann E.: Mechanisms of teratogenesis: Folic acid and antiepileptic therapy. Neurology1992;42 (Suppl 5):32-42.
71.
Smith Pem, Myson V., Gibbon F.: A teenager epilepsy clinic: Observational study. Eur J Neurol2002; 9: 373—376.
72.
Practice parameter: Management issues for woman with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology1998;51:944—948.
73.
Meischenguiser R., D'Giano CH, Ferraro SM: Oxcarbazepine in pregnancy: Clinical experience in Argentina. Epilepsy Behav2004;5:163—167.
74.
Tennis P., Eldridge RR, and the InternationalLamotrigine Pregnancy Registry Scientific Advisory Committee: Preliminary results on pregnancy outcomes in women using lamotrigine . Epilepsia2002;43:1161—1167.
75.
Sabers A., Dam M., A-Rogvi-Hansen B., et al: Epilepsy and pregnancy: Lamotrigine as main drug used. Acta Neurol Scand2004;109:9—13.
76.
Pennell PB, Newport DJ, Stowe ZN, et al: The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology2004;62:292—295.
77.
Isoherranen N., Spiegelstein O., Bialer M., et al: Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-α-ethyloxo-pyrrolidine acetamide in a mouse model of teratogenicity . Epilepsia2003;44:1280—1288.
78.
Holmes LB, Wyszynski DF, Lieberman E.: The AED (antiepileptic drug) pregnancy registry: A 6-year experience. Arch Neurol2004;61:673—678.
79.
Crawford P. , Appleton R., Betts T., et al: Best practice guidelines for the management of women with epilepsy. Seizure1999;8:201—217.
80.
Isojärvi JI : Reproductive dysfunction in women with epilepsy . Neurology2003; 61 (Suppl 2):S27—S34.
81.
Mikkonen K. , Vainionpää LK, Pakarinen AJ, et al: Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology2004; 62: 445—450.
82.
Bilo L., Meo R., Valentino R., et al: Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab2001 ;86:2950—2956.
83.
Bauer J., Isojärvi Jit, Herzog AG, et al: Reproductive dysfunction in women with epilepsy: Recommendations for evaluation and management. J Neurol Neurosurg Psychiatry2002;73:121—125.
84.
Mikkonen K. , Tapanainen P., Pakarinen AJ, et al: Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsy2004; 45: 769—776.
85.
Appleton RE , Neville Bgr: Teenagers with epilepsy. Arch Dis Child1999;81:76—79.
86.
Shorvon SD, Tallis RC, Wallace HK: Antiepileptic drugs: Coprescription of proconvulsant drugs and oral contraceptives: A national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry2002; 72: 114—115.
87.
Doose DR, Wang S-S., Padmanabhan M., et al: Effects of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia2003;44:540—549.
88.
Gil-Nagel A. : Review of new antiepileptic drugs as initial therapy. Epilepsia2003;44(Suppl 4):3—10.
89.
Perucca E., Dulac O., Shorvon S., Tomson T.: Harnessing the clinical potential of antiepileptic drug therapy: Dosage optimisation. CNSDrugs2001;15:609—621.
90.
Perucca E.: Current trends in antiepileptic drug therapy. Epilepsia2003;44(Suppl 4):41—47.
